{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:02:10Z","timestamp":1787497330023,"version":"build-2736575974"},"reference-count":166,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004505","name":"University of Catania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ejim.2025.06.010","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T19:40:06Z","timestamp":1749843606000},"page":"6-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["A holistic view of SGLT2 inhibitors: From cardio-renal management to cognitive and andrological aspects"],"prefix":"10.1016","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4599-8487","authenticated-orcid":false,"given":"Rossella","family":"Cannarella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Rubulotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Cannarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"La Vignera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo E.","family":"Calogero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejim.2025.06.010_bib0110","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12551-015-0186-2","article-title":"Glucose transporters: physiological and pathological roles","volume":"8","author":"Navale","year":"2016","journal-title":"Biophys Rev"},{"issue":"5","key":"10.1016\/j.ejim.2025.06.010_bib0132","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/MNH.0000000000000152","article-title":"Sodium-glucose cotransport","volume":"24","author":"Poulsen","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"Suppl 5","key":"10.1016\/j.ejim.2025.06.010_bib0080","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1016\/j.jcjd.2015.09.001","article-title":"The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes","volume":"39","author":"Katz","year":"2015","journal-title":"Can J Diabetes"},{"issue":"12","key":"10.1016\/j.ejim.2025.06.010_bib0048","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1080\/17425255.2018.1551877","article-title":"The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments","volume":"14","author":"Garcia-Ropero","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"Suppl 1","key":"10.1016\/j.ejim.2025.06.010_bib0006","first-page":"S98","article-title":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2025.06.010_bib0018","first-page":"487","volume":"43","author":"Buse","year":"2020"},{"issue":"12","key":"10.1016\/j.ejim.2025.06.010_bib0038","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.ejim.2025.06.010_bib0056","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s13300-024-01538-1","article-title":"Risk of Dementia in Patients with Diabetes Using Sodium-Glucose Transporter 2 Inhibitors (SGLT2i): A Systematic Review, Meta-Analysis, and Meta-Regression","volume":"15","author":"Gunawan","year":"2024","journal-title":"Diabetes Ther"},{"issue":"1","key":"10.1016\/j.ejim.2025.06.010_bib0097","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12902-023-01476-2","article-title":"Risk factors for cognitive dysfunction and glycemic management in older adults with type 2 diabetes mellitus: a retrospective study","volume":"23","author":"Ma","year":"2023","journal-title":"BMC Endocr Disord"},{"issue":"3","key":"10.1016\/j.ejim.2025.06.010_bib0011","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/0003-4819-139-3-200308050-00005","article-title":"Sexual function in men older than 50 years of age: results from the health professionals follow-up study","volume":"139","author":"Bacon","year":"2003","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.ejim.2025.06.010_bib0114","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0090-4295(02)02102-7","article-title":"Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction","volume":"61","author":"Nicolosi","year":"2003","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.ejim.2025.06.010_bib0115","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jama.1993.03510010089036","article-title":"NIH Consensus Development Panel on Impotence","volume":"270","year":"1993","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ejim.2025.06.010_bib0118","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.4103\/jfmpc.jfmpc_1130_21","article-title":"Prevalence of erectile dysfunction in Type 2 diabetes mellitus (T2DM) and its predictors among diabetic men","volume":"11","author":"Parmar","year":"2022","journal-title":"J Family Med Prim Care"},{"issue":"4","key":"10.1016\/j.ejim.2025.06.010_bib0122","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2337\/diaspect.17.4.225","article-title":"Erectile Dysfunction in Diabetic Patients","volume":"17","author":"Penson","year":"2004","journal-title":"Diabetes Spectr"},{"key":"10.1016\/j.ejim.2025.06.010_bib0032","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3389\/fendo.2018.00268","article-title":"Diabetes Mellitus and Infertility: Different Pathophysiological Effects in Type 1 and Type 2 on Sperm Function","volume":"9","author":"Condorelli","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"10.1016\/j.ejim.2025.06.010_bib0124","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jdiacomp.2016.04.002","article-title":"Diabetes mellitus and functional sperm characteristics: A meta-analysis of observational studies","volume":"30","author":"Pergialiotis","year":"2016","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.ejim.2025.06.010_bib0047","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrates utilization in response to sodium-glucose co-transporter-2 inhibition in nondiabetic subjects and type 2 diabetic patients","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2025.06.010_bib0109","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the empa-reg outcome study? a unifying Hypothesis","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2025.06.010_bib0059","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejim.2025.06.010_bib0065","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.3390\/jcm8111814","article-title":"The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes","volume":"8","author":"Iannantuoni","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejim.2025.06.010_bib0072","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4,placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.ejim.2025.06.010_bib0028","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/07853890.2017.1417631","article-title":"The role of mitochondrial dysfunction in cardiovascular disease: a brief review","volume":"50","author":"Chistiakov","year":"2018","journal-title":"Ann Med"},{"key":"10.1016\/j.ejim.2025.06.010_bib0063","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6392763","article-title":"The Role of the Antioxidant Response in Mitochondrial Dysfunction in Degenerative Diseases: Cross-Talk between Antioxidant Defense, Autophagy, and Apoptosis","author":"Huang","year":"2019","journal-title":"Oxid Med Cell Longev"},{"issue":"2","key":"10.1016\/j.ejim.2025.06.010_bib0128","doi-asserted-by":"crossref","first-page":"E268","DOI":"10.1152\/ajpendo.00314.2018","article-title":"Mitochondrial dysfunction in type 2 diabetes mellitus: an organ-based analysis","volume":"316","author":"Pinti","year":"2019","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.ejim.2025.06.010_bib0159","first-page":"53","article-title":"Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions: state of the art","volume":"22","author":"Yaribeygi","year":"2023","journal-title":"EXCLI J"},{"key":"10.1016\/j.ejim.2025.06.010_bib0116","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamacardio.2017.2275","article-title":"Effects of sodiumglucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action","volume":"2","author":"Packer","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejim.2025.06.010_bib0026","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"10.1016\/j.ejim.2025.06.010_bib0084","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.3390\/ijms25073583","article-title":"The Role of Epicardial Adipose Tissue in Acute Coronary Syndromes, Post-Infarct Remodeling and Cardiac Regeneration","volume":"25","author":"Krauz","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejim.2025.06.010_bib0127","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12933-017-0511-0","article-title":"Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness inpatients with type 2 diabetes mellitus: a post hoc analysis","volume":"16","author":"Pfeifer","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"45","key":"10.1016\/j.ejim.2025.06.010_bib0130","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1093\/eurheartj\/ehac417","article-title":"Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?","volume":"43","author":"Pitt","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ejim.2025.06.010_bib0024","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12933-019-0828-y","article-title":"the first dual SGLT inhibitor: current outlook and perspectives","volume":"18","author":"Cefalo","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"10.1016\/j.ejim.2025.06.010_bib0117","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.jacc.2021.01.033","article-title":"EMPEROR-Reduced Trial Committees and Investigators. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial","volume":"77","author":"Packer","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.ejim.2025.06.010_bib0008","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2025.06.010_bib0010","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12933-023-01920-6","article-title":"Alterations in trimethylamine-N-oxide in response to Empagliflozin therapy: a secondary analysis of the EMMY trial","volume":"22","author":"Aziz","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"19","key":"10.1016\/j.ejim.2025.06.010_bib0019","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.jacc.2023.03.390","article-title":"Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories","volume":"81","author":"Butler","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.ejim.2025.06.010_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2022.101418","article-title":"Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study","volume":"49","author":"Karasik","year":"2023","journal-title":"Diabetes Metab"},{"issue":"41","key":"10.1016\/j.ejim.2025.06.010_bib0149","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1093\/eurheartj\/ehac494","article-title":"Empagliflozin in acute myocardial infarction: the EMMY trial","volume":"43","author":"Von Lewinski","year":"2022","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.ejim.2025.06.010_bib0165","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.06.010_bib0112","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"CANVAS Pro-gram Collaborative Group. Canagliflozin and Cardio-vascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejim.2025.06.010_bib0134","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","article-title":"Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program","volume":"138","author":"R\u00e5dholm","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ejim.2025.06.010_bib0163","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1161\/STROKEAHA.118.023009","article-title":"Canagliflozin and Stroke in Type 2 Diabetes Mellitus","volume":"50","author":"Zhou","year":"2019","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.ejim.2025.06.010_bib0098","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)","volume":"137","author":"Mahaffey","year":"2018","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ejim.2025.06.010_bib0154","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"DECLARE\u2013TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ejim.2025.06.010_bib0103","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ejim.2025.06.010_bib0142","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"DELIVER Trial Committees and Investigators. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejim.2025.06.010_bib0069","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evid"},{"issue":"15","key":"10.1016\/j.ejim.2025.06.010_bib0022","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"VERTIS CV Investigators. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med."},{"issue":"23","key":"10.1016\/j.ejim.2025.06.010_bib0035","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/CIRCULATIONAHA.120.050255","article-title":"VERTIS CV Investigators. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial","volume":"142","author":"Cosentino","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2025.06.010_bib0054","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.amjms.2019.09.002","article-title":"Gut microbial metabolite trimethylamine N-oxide is related to thrombus formation in atrial fbrillation patients","volume":"358","author":"Gong","year":"2019","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.ejim.2025.06.010_bib0091","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1002\/ehf2.14009","article-title":"Association between trimethylamine N-oxide and prognosis of patients with acute myocardial infarction and heart failure","volume":"9","author":"Li","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2025.06.010_bib0092","first-page":"814","article-title":"Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors","volume":"38","author":"Li","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2025.06.010_bib0150","doi-asserted-by":"crossref","first-page":"231","DOI":"10.31083\/j.rcm.2021.01.299","article-title":"Trimethylamine N-oxide is associated with coronary atherosclerotic burden in non-STsegment myocardial infarction patients: SZ-NSTEMI prospective cohort study","volume":"22","author":"Waleed","year":"2021","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.ejim.2025.06.010_bib0155","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/1751-7915.13524","article-title":"The gut microbiota and its interactions with cardiovascular disease","volume":"13","author":"Xu","year":"2020","journal-title":"Micriob Biotechnol"},{"key":"10.1016\/j.ejim.2025.06.010_bib0162","first-page":"188","article-title":"Trimethylamine N-oxide and cardiovascular outcomes in patients with chronic heart failure after myocardial infarction","volume":"7","author":"Zhou","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2025.06.010_bib0151","article-title":"Effects of oral glucose lowering agents on gut microbiota and microbial metabolites","volume":"13","author":"Wang","year":"2022","journal-title":"Front Endocrinol"},{"issue":"7","key":"10.1016\/j.ejim.2025.06.010_bib0111","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2025.06.010_bib0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/eurheartj\/ehac530","article-title":"Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial","volume":"44","author":"Biegus","year":"2023","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.ejim.2025.06.010_bib0046","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","article-title":"Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials","volume":"18","author":"Fernandes","year":"2021","journal-title":"Heart Rhythm"},{"issue":"36","key":"10.1016\/j.ejim.2025.06.010_bib0036","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1093\/eurheartj\/ehab560","article-title":"Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF","volume":"42","author":"Curtain","year":"2021","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.ejim.2025.06.010_bib0004","doi-asserted-by":"crossref","first-page":"10191","DOI":"10.1007\/s00210-024-03224-2","article-title":"The effects of empagliflozin on ventricular arrhythmias in heart failure patients with an implantable cardioverter-defibrillator: a double-blind randomized controlled trial","volume":"397","author":"Abedi","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"3","key":"10.1016\/j.ejim.2025.06.010_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.101615","article-title":"Sodium-Glucose Cotransporter-2 Inhibitors and Arrhythmias: A Meta-Analysis of 38 Randomized Controlled Trials","volume":"4","author":"Jaiswal","year":"2025","journal-title":"JACC Adv"},{"issue":"39","key":"10.1016\/j.ejim.2025.06.010_bib0177","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"issue":"Supplement_1","key":"10.1016\/j.ejim.2025.06.010_bib0179","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2025.06.010_bib0039","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2011.861","article-title":"Temporal trends in the prevalence of diabetic kidney disease in the United States","volume":"305","author":"De Boer","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2025.06.010_bib0057","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization?. A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.ejim.2025.06.010_bib0051","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12933-020-01163-9","article-title":"Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk","volume":"19","author":"Giorgino","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.ejim.2025.06.010_bib0144","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in Patients with Chronic Kidney Disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejim.2025.06.010_bib0152","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ejim.2025.06.010_bib0126","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejim.2025.06.010_bib0070","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1681\/ASN.2019111168","article-title":"Perkovic V; CREDENCE Study Investigators. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial","volume":"31","author":"Jardine","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"15","key":"10.1016\/j.ejim.2025.06.010_bib0060","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2025.06.010_bib0102","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2022.4210","article-title":"Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial","volume":"8","author":"Mc Causland","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"8","key":"10.1016\/j.ejim.2025.06.010_bib0108","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.ejim.2025.06.010_bib0027","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1007\/s00125-021-05407-5","article-title":"VERTIS CV Investigators. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial","volume":"64","author":"Cherney","year":"2021","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.ejim.2025.06.010_bib0045","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","article-title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial","volume":"12","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.ejim.2025.06.010_bib0044","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S2213-8587(23)00321-2","article-title":"Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial","volume":"12","author":"Group","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.ejim.2025.06.010_bib0005","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3233\/JAD-191115","article-title":"Prevalence and Incidence of Dementia in People with Diabetes Mellitus","volume":"75","author":"Alsharif","year":"2020","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"10.1016\/j.ejim.2025.06.010_bib0160","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00592-020-01648-9","article-title":"The prevalence of mild cognitive impairment in type 2 diabetes mellitus patients: a systematic review and meta-analysis","volume":"58","author":"You","year":"2021","journal-title":"Acta Diabetol"},{"issue":"6","key":"10.1016\/j.ejim.2025.06.010_bib0055","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/jdi.12087","article-title":"Diabetes mellitus and risk of dementia: A meta-analysis of prospective observational studies","volume":"4","author":"Gudala","year":"2013","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.ejim.2025.06.010_bib0156","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2019.100944","article-title":"Diabetes mellitus and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 144 prospective studies","volume":"55","author":"Xue","year":"2019","journal-title":"Ageing Res Rev"},{"issue":"10","key":"10.1016\/j.ejim.2025.06.010_bib0016","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41574-018-0048-7","article-title":"Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications","volume":"14","author":"Biessels","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ejim.2025.06.010_bib0104","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.brainresbull.2022.01.018","article-title":"Dementia in diabetes mellitus and atherosclerosis: Two interrelated systemic diseases","volume":"181","author":"Mohseni-Moghaddam","year":"2022","journal-title":"Brain Res Bull"},{"issue":"9","key":"10.1016\/j.ejim.2025.06.010_bib0164","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11892-016-0775-x","article-title":"Diabetes and Cognitive Impairment","volume":"16","author":"Zilliox","year":"2016","journal-title":"Curr Diab Rep"},{"issue":"23","key":"10.1016\/j.ejim.2025.06.010_bib0120","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.3390\/molecules26237213","article-title":"Neuroprotective Effect of SGLT2 Inhibitors","volume":"26","author":"Pawlos","year":"2021","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.ejim.2025.06.010_bib0067","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12933-018-0695-y","article-title":"Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy","volume":"17","author":"Irace","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ejim.2025.06.010_bib0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106062","article-title":"Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment","volume":"176","author":"Rizzo","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ejim.2025.06.010_bib0137","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.taap.2017.08.005","article-title":"SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats","volume":"333","author":"Sa-Nguanmoo","year":"2017","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.ejim.2025.06.010_bib0121","doi-asserted-by":"crossref","unstructured":"Pawlos A, Broncel M, Wo\u017aniak E, Gorzelak-Pabi\u015b P. Neuroprotective Effect of SGLT2 Inhibitors. Molecules. 2021 Nov 28;26(23):7213. doi: 10.3390\/molecules26237213. PMID: 34885795; PMCID: PMC8659196.","DOI":"10.3390\/molecules26237213"},{"issue":"11","key":"10.1016\/j.ejim.2025.06.010_bib0043","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.3390\/medicina60111805","article-title":"Repositioning Canagliflozin for Mitigation of Aluminium Chloride-Induced Alzheimer's Disease: Involvement of TXNIP\/NLRP3 Inflammasome Axis, Mitochondrial Dysfunction, and SIRT1\/HMGB1 Signalling","volume":"60","author":"Elariny","year":"2024","journal-title":"Medicina (Kaunas)."},{"issue":"11","key":"10.1016\/j.ejim.2025.06.010_bib0166","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.3390\/ph16111620","article-title":"Preclinical Studies of Canagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, and Donepezil Combined Therapy in Alzheimer's Disease","volume":"16","author":"Stanciu","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"10.1016\/j.ejim.2025.06.010_bib0168","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.3390\/biomedicines11113000","article-title":"Targeting Autophagy, Apoptosis, and Oxidative Perturbations with Dapagliflozin Mitigates Cadmium-Induced Cognitive Dysfunction in Rats","volume":"11","author":"Arab","year":"2023","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.ejim.2025.06.010_bib0169","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3390\/ph16050753","article-title":"Dapagliflozin Ameliorates Cognitive Impairment in Aluminum-Chloride-Induced Alzheimer's Disease via Modulation of AMPK\/mTOR, Oxidative Stress and Glucose Metabolism","volume":"16","author":"Samman","year":"2023","journal-title":"Pharmaceuticals (Basel)."},{"issue":"6","key":"10.1016\/j.ejim.2025.06.010_bib0170","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1007\/s10787-022-00973-5","article-title":"Dapagliflozin as an autophagic enhancer via LKB1\/AMPK\/SIRT1 pathway in ovariectomized\/D-galactose Alzheimer's rat model","volume":"30","author":"Ibrahim","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.ejim.2025.06.010_bib0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2023.114134","article-title":"The sodium glucose co-transporter 2 inhibitor ertugliflozin for Alzheimer's disease: Inhibition of brain insulin signaling disruption-induced tau hyperphosphorylation","volume":"263","author":"Pang","year":"2023","journal-title":"Physiol Behav"},{"issue":"5","key":"10.1016\/j.ejim.2025.06.010_bib0105","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2337\/dc21-2434","article-title":"Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction","volume":"45","author":"Mone","year":"2022","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.ejim.2025.06.010_bib0171","first-page":"1251","article-title":"Effect of Dapagliflozin Combined with Cognitive Behavior Training on Quality of Life and Cognitive Function in Elderly Patients with Type 2 Diabetes Mellitus Complicated with Mild Cognitive Impairment","volume":"51","author":"Zhao","year":"2022","journal-title":"Iran J Public Health"},{"issue":"6","key":"10.1016\/j.ejim.2025.06.010_bib0172","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2025.109017","article-title":"Inflammation levels in type 2 diabetes mellitus patients with mild cognitive impairment: Assessment followed by amelioration via dapagliflozin therapy","volume":"39","author":"Zhang","year":"2025","journal-title":"J Diabetes Complications"},{"issue":"9","key":"10.1016\/j.ejim.2025.06.010_bib0083","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/dme.13403","article-title":"High prevalence of erectile dysfunction in diabetes: a systematic review and meta-analysis of 145 studies","volume":"34","author":"Kouidrat","year":"2017","journal-title":"Diabet Med"},{"issue":"3","key":"10.1016\/j.ejim.2025.06.010_bib0012","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/0003-4819-139-3-200308050-00005","article-title":"Sexual function in men older than 50 years of age: results from the health professionals follow-up study","volume":"139","author":"Bacon","year":"2003","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.ejim.2025.06.010_bib0071","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0022-5347(05)67900-1","article-title":"Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study","volume":"163","author":"Johannes","year":"2000","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ejim.2025.06.010_bib0079","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3390\/medicina59050969","article-title":"The Associations between Kidney Function and Sexual Dysfunction among Males and Females with Type 2 Diabetes Mellitus","volume":"59","author":"Katsimardou","year":"2023","journal-title":"Medicina (Kaunas)."},{"issue":"12B","key":"10.1016\/j.ejim.2025.06.010_bib0107","doi-asserted-by":"crossref","first-page":"19M","DOI":"10.1016\/j.amjcard.2005.07.006","article-title":"The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease","volume":"96","author":"Montorsi","year":"2005","journal-title":"Am J Cardiol"},{"issue":"13","key":"10.1016\/j.ejim.2025.06.010_bib0040","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jacc.2011.06.024","article-title":"Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies","volume":"58","author":"Dong","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ejim.2025.06.010_bib0148","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1161\/CIRCOUTCOMES.112.966903","article-title":"Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies","volume":"6","author":"Vlachopoulos","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"7","key":"10.1016\/j.ejim.2025.06.010_bib0161","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jsxm.2019.04.004","article-title":"Erectile Dysfunction Predicts Cardiovascular Events as an Independent Risk Factor: A Systematic Review and Meta-Analysis","volume":"16","author":"Zhao","year":"2019","journal-title":"J Sex Med"},{"issue":"9","key":"10.1016\/j.ejim.2025.06.010_bib0009","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jsxm.2018.07.002","article-title":"The Favorable Effect of Empagliflozin on Erectile Function in an Experimental Model of Type 2 Diabetes","volume":"15","author":"Assaly","year":"2018","journal-title":"J Sex Med"},{"issue":"6","key":"10.1016\/j.ejim.2025.06.010_bib0101","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1159\/000049850","article-title":"Prognostic factors for response to sildenafil in patients with erectile dysfunction","volume":"40","author":"Mart\u00ednez-Jabaloyas","year":"2001","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.ejim.2025.06.010_bib0113","first-page":"387","article-title":"The use of sildenafil in patients with erectile dysfunction in relation to diabetes mellitus\u2013a study of 1,511 patients","volume":"43","author":"Ng","year":"2002","journal-title":"Singapore Med J"},{"issue":"3","key":"10.1016\/j.ejim.2025.06.010_bib0030","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejim.2013.01.001","article-title":"Arterial erectile dysfunction: different severities of endothelial apoptosis between diabetic patients \"responders\" and \"non responders\" to sildenafil","volume":"24","author":"Condorelli","year":"2013","journal-title":"Eur J Intern Med"},{"issue":"3","key":"10.1016\/j.ejim.2025.06.010_bib0053","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2337\/diacare.26.3.777","article-title":"Vardenafil Diabetes Study Group. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study","volume":"26","author":"Goldstein","year":"2003","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.ejim.2025.06.010_bib0100","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/j.1743-6109.2008.01168.x","article-title":"Erectile dysfunction in diabetes mellitus","volume":"6","author":"Malavige","year":"2009","journal-title":"J Sex Med"},{"issue":"7","key":"10.1016\/j.ejim.2025.06.010_bib0119","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.4103\/jfmpc.jfmpc_1130_21","article-title":"Prevalence of erectile dysfunction in Type 2 diabetes mellitus (T2DM) and its predictors among diabetic men","volume":"11","author":"Parmar","year":"2022","journal-title":"J Family Med Prim Care"},{"issue":"2 Pt 1","key":"10.1016\/j.ejim.2025.06.010_bib0007","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1743-6109.2009.01587.x","article-title":"Diabetes exacerbates the functional deficiency of NO\/cGMP pathway associated with erectile dysfunction in human corpus cavernosum and penile arteries","volume":"7","author":"Angulo","year":"2010","journal-title":"J Sex Med"},{"issue":"16","key":"10.1016\/j.ejim.2025.06.010_bib0136","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1056\/NEJM198904203201601","article-title":"Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence","volume":"320","author":"Saenz de Tejada","year":"1989","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2025.06.010_bib0020","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/13685538.2018.1434772","article-title":"Epidemiology and risk factors of lower urinary tract symptoms\/benign prostatic hyperplasia and erectile dysfunction","volume":"22","author":"Calogero","year":"2019","journal-title":"Aging Male"},{"issue":"1","key":"10.1016\/j.ejim.2025.06.010_bib0021","doi-asserted-by":"crossref","DOI":"10.1111\/dme.15217","article-title":"La Vignera S. Dapagliflozin improves erectile dysfunction in patients with type 2 diabetes mellitus: An open-label, non-randomized pilot study","volume":"41","author":"Cannarella","year":"2024","journal-title":"Diabet Med"},{"key":"10.1016\/j.ejim.2025.06.010_bib0146","doi-asserted-by":"crossref","first-page":"865","DOI":"10.33594\/000000178","article-title":"Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor a-stimulated human coronary arterial endothelial cells","volume":"53","author":"Uthman","year":"2019","journal-title":"Cell Physiol Biochem"},{"issue":"5","key":"10.1016\/j.ejim.2025.06.010_bib0147","doi-asserted-by":"crossref","first-page":"865","DOI":"10.33594\/000000178","article-title":"Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor \u03b1-Stimulated Human Coronary Arterial Endothelial Cells","volume":"53","author":"Uthman","year":"2019","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.ejim.2025.06.010_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112628","article-title":"The dynamic interplay between AMPK\/NF\u03baB signaling and NLRP3 is a new therapeutic target in inflammation: Emerging role of dapagliflozin in overcoming lipopolysaccharide-mediated lung injury","volume":"147","author":"Abd El-Fattah","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"10.1016\/j.ejim.2025.06.010_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09503","article-title":"Dapagliflozin induces vasodilation in resistance-size mesenteric arteries by stimulating smooth muscle cell KV7 ion channels","volume":"8","author":"Hasan","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.ejim.2025.06.010_bib0073","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.926717","article-title":"The Outcomes of Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2I) on Diabetes-Associated Neuropathy: A Systematic Review and meta-Analysis","volume":"13","author":"Kandeel","year":"2022","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.ejim.2025.06.010_bib0086","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s12020-020-02518-8","article-title":"The ketogenic diet corrects metabolic hypogonadism and preserves pancreatic \u00df-cell function in overweight\/obese men: a single-arm uncontrolled study","volume":"72","author":"La Vignera","year":"2021","journal-title":"Endocrine"},{"issue":"10","key":"10.1016\/j.ejim.2025.06.010_bib0106","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.3390\/nu12102967","article-title":"Effectiveness of a Very Low Calorie Ketogenic Diet on Testicular Function in Overweight\/Obese Men","volume":"12","author":"Mongio\u00ec","year":"2020","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.ejim.2025.06.010_bib0062","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/FJC.0000000000001624","article-title":"Erectile Dysfunction Risk Among Patients With Diabetes Mellitus Using Sodium-Glucose Cotransporter 2 Inhibitors","volume":"84","author":"Hu","year":"2024","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ejim.2025.06.010_bib0157","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2147\/DMSO.S503216","article-title":"Effects of Anti-Diabetic Drugs on Erectile Dysfunction: A Systematic Review and Meta-Analysis","volume":"18","author":"Yang","year":"2025","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"10.1016\/j.ejim.2025.06.010_bib0138","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/JU.0000000000001520","article-title":"Diagnosis and Treatment of Infertility in Men: AUA\/ASRM Guideline PART II","volume":"205","author":"Schlegel","year":"2021","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ejim.2025.06.010_bib0064","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s10020-023-00771-x","article-title":"Diabetes-induced male infertility: potential mechanisms and treatment options","volume":"30","author":"Huang","year":"2024","journal-title":"Mol Med"},{"key":"10.1016\/j.ejim.2025.06.010_bib0089","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S2213-8587(17)30186-9","article-title":"Type 2 diabetes in adolescents and young adults","volume":"6","author":"Lascar","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.ejim.2025.06.010_bib0017","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/pd.5402","article-title":"Advanced paternal age, infertility, and reproductive risks: A review of the literature","volume":"39","author":"Brandt","year":"2019","journal-title":"Prenat Diagn"},{"issue":"1","key":"10.1016\/j.ejim.2025.06.010_bib0085","first-page":"1","article-title":"Andrological characterization of the patient with diabetes mellitus","volume":"34","author":"La Vignera","year":"2009","journal-title":"Minerva Endocrinol"},{"key":"10.1016\/j.ejim.2025.06.010_bib0096","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jri.2017.08.007","article-title":"Effect of diabetes mellitus on the quality and cytokine content of human semen","volume":"123","author":"Lu","year":"2017","journal-title":"J Reprod Immunol"},{"issue":"1","key":"10.1016\/j.ejim.2025.06.010_bib0001","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12958-022-01034-w","article-title":"How much obesity and diabetes do impair male fertility?","volume":"21","author":"AbbasiHormozi","year":"2023","journal-title":"Reprod Biol Endocrinol"},{"issue":"6","key":"10.1016\/j.ejim.2025.06.010_bib0140","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.fertnstert.2023.10.017","article-title":"The impact of obesity and metabolic health on male fertility: a systematic review","volume":"120","author":"Service","year":"2023","journal-title":"Fertil Steril"},{"issue":"5","key":"10.1016\/j.ejim.2025.06.010_bib0013","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.dsx.2020.07.031","article-title":"Diabetes mellitus and the impairment of male reproductive function: Possible signaling pathways","volume":"14","author":"Barkabi-Zanjani","year":"2020","journal-title":"Diabetes Metab Syndr"},{"issue":"5","key":"10.1016\/j.ejim.2025.06.010_bib0131","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1210\/jc.2004-2190","article-title":"Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men","volume":"90","author":"Pitteloud","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ejim.2025.06.010_bib0125","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jdiacomp.2016.04.002","article-title":"Diabetes mellitus and functional sperm characteristics: A meta-analysis of observational studies","volume":"30","author":"Pergialiotis","year":"2016","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.ejim.2025.06.010_bib0033","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3389\/fendo.2018.00268","article-title":"Diabetes Mellitus and Infertility: Different Pathophysiological Effects in Type 1 and Type 2 on Sperm Function","volume":"9","author":"Condorelli","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ejim.2025.06.010_bib0087","doi-asserted-by":"crossref","DOI":"10.1177\/2058738419866582","article-title":"Urogenital infections in patients with diabetes mellitus: Beyond the conventional aspects","volume":"33","author":"La Vignera","year":"2019","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"5","key":"10.1016\/j.ejim.2025.06.010_bib0034","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4103\/1008-682X.125911","article-title":"La Vignera S. Male accessory gland inflammation prevalence in type 2 diabetic patients with symptoms possibly reflecting autonomic neuropathy","volume":"16","author":"Condorelli","year":"2014","journal-title":"Asian J Androl"},{"issue":"2","key":"10.1016\/j.ejim.2025.06.010_bib0088","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1016\/j.ejrad.2010.08.001","article-title":"Ultrasound characterization of the seminal vesicles in infertile patients with type 2 diabetes mellitus","volume":"80","author":"La Vignera","year":"2011","journal-title":"Eur J Radiol"},{"issue":"9","key":"10.1016\/j.ejim.2025.06.010_bib0031","first-page":"770","article-title":"Prevalence of male accessory gland inflammations\/infections in patients with Type 2 diabetes mellitus","volume":"36","author":"Condorelli","year":"2013","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ejim.2025.06.010_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1059942","article-title":"Effects of empagliflozin on the expression of kisspeptin gene and reproductive system function in streptozotocin-induced diabetic male rats","volume":"13","author":"Dana","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ejim.2025.06.010_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116135","article-title":"Empagliflozin reduces the adverse effects of diabetes mellitus on testicular tissue in type 2 diabetic rats: A stereological and biochemical study","volume":"223","author":"Kiani","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ejim.2025.06.010_bib0099","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1145111","article-title":"Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders","volume":"14","author":"Maiorana","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.ejim.2025.06.010_bib0052","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13098-022-00951-5","article-title":"The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial","volume":"14","author":"Gohari","year":"2022","journal-title":"Diabetol Metab Syndr"},{"issue":"26","key":"10.1016\/j.ejim.2025.06.010_bib0014","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.3748\/wjg.v28.i26.3243","article-title":"Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis\/fibrosis\/inflammation and redox balance in non-alcoholic fatty liver disease","volume":"28","author":"Bellanti","year":"2022","journal-title":"World J Gastroenterol"},{"issue":"7","key":"10.1016\/j.ejim.2025.06.010_bib0003","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s12272-022-01391-5","article-title":"Empagliflozin mitigates type 2 diabetes-associated peripheral neuropathy: a glucose-independent effect through AMPK signaling","volume":"45","author":"Abdelkader","year":"2022","journal-title":"Arch Pharm Res"},{"issue":"2","key":"10.1016\/j.ejim.2025.06.010_bib0066","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/1479164114559852","article-title":"SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials","volume":"12","author":"Inzucchi","year":"2015","journal-title":"Diab Vasc Dis Res"},{"issue":"3","key":"10.1016\/j.ejim.2025.06.010_bib0050","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/andr.12754","article-title":"Weight loss more than glycemic control may improve testosterone in obese type 2 diabetes mellitus men with hypogonadism","volume":"8","author":"Giagulli","year":"2020","journal-title":"Andrology"},{"issue":"1","key":"10.1016\/j.ejim.2025.06.010_bib0173","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41598-024-51224-2","article-title":"Dapagliflozin ameliorates diabetes-induced spermatogenic dysfunction by modulating the adenosine metabolism along the gut microbiota-testis axis","volume":"14","author":"Jin","year":"2024","journal-title":"Sci Rep."},{"issue":"7","key":"10.1016\/j.ejim.2025.06.010_bib0175","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.3390\/ph16071006","article-title":"Stimulation of Autophagy by Dapagliflozin Mitigates Cadmium-Induced Testicular Dysfunction in Rats: The Role of AMPK\/mTOR and SIRT1\/Nrf2\/HO-1 Pathways","volume":"16","author":"Arab","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"10.1016\/j.ejim.2025.06.010_bib0176","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.70257","article-title":"Modulation of AMPK\/mTOR Autophagic Pathway Using Dapagliflozin Protects Against Cadmium-Induced Testicular and Renal Injury in Rats","volume":"39","author":"Dagher","year":"2025","journal-title":"J Biochem Mol Toxicol"},{"issue":"1","key":"10.1016\/j.ejim.2025.06.010_bib0093","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13098-025-01700-0","article-title":"Protective effect of antidiabetic drugs against male infertility: evidence from Mendelian randomization","volume":"17","author":"Li","year":"2025","journal-title":"Diabetol Metab Syndr"},{"issue":"12","key":"10.1016\/j.ejim.2025.06.010_bib0049","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1080\/17425255.2018.1551877","article-title":"The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments","volume":"14","author":"Garcia-Ropero","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"19","key":"10.1016\/j.ejim.2025.06.010_bib0139","first-page":"339","article-title":"Urogenital Infection as a Risk Factor for Male Infertility","volume":"114","author":"Schuppe","year":"2017","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"10.1016\/j.ejim.2025.06.010_bib0023","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s13300-021-01004-2","article-title":"Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies","volume":"12","author":"Caparrotta","year":"2021","journal-title":"Diabetes Ther"},{"issue":"2","key":"10.1016\/j.ejim.2025.06.010_bib0133","doi-asserted-by":"crossref","DOI":"10.1177\/14791641211011016","article-title":"Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors","volume":"18","author":"Qiu","year":"2021","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.ejim.2025.06.010_bib0143","first-page":"1","article-title":"Genito-urinary infectious adverse events related to sodium glucose cotransporter-2 inhibitors: a network meta-analysis and meta-regression","author":"Sridharan","year":"2024","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ejim.2025.06.010_bib0041","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022577","article-title":"Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis","volume":"9","author":"Donnan","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejim.2025.06.010_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1256548","article-title":"Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials","volume":"14","author":"Chen","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"10.1016\/j.ejim.2025.06.010_bib0042","doi-asserted-by":"crossref","first-page":"E594","DOI":"10.9778\/cmajo.20180111","article-title":"Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials","volume":"6","author":"Donnan","year":"2018","journal-title":"CMAJ Open"},{"issue":"12","key":"10.1016\/j.ejim.2025.06.010_bib0145","first-page":"59","article-title":"The Incidence and Risk Factors of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Using SGLT2 Inhibitors: A Real-World Observational Study","volume":"9","author":"Uitrakul","year":"2022","journal-title":"Medicines (Basel)"},{"issue":"3","key":"10.1016\/j.ejim.2025.06.010_bib0141","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s13300-019-0611-9","article-title":"A Survey of the FDA's Adverse Event Reporting System Database Concerning Urogenital Tract Infections and Sodium Glucose Cotransporter-2 Inhibitor Use","volume":"10","author":"Shen","year":"2019","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.ejim.2025.06.010_bib0158","first-page":"1","article-title":"Urinary tract infections and genital mycotic infections associated with SGLT2 inhibitors: an analysis of the FDA Adverse Event Reporting System","author":"Yang","year":"2023","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"10.1016\/j.ejim.2025.06.010_bib0129","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11892-024-01537-3","article-title":"Diabetes, SGLT-2 Inhibitors, and Urinary Tract Infection: a Review","volume":"24","author":"Pishdad","year":"2024","journal-title":"Curr Diab Rep"},{"issue":"8","key":"10.1016\/j.ejim.2025.06.010_bib0094","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/nep.14167","article-title":"Practical considerations for the use of SGLT-2 inhibitors in the Asia-Pacific countries-An expert consensus statement","volume":"28","author":"Liew","year":"2023","journal-title":"Nephrology (Carlton)"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095362052500247X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095362052500247X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T15:04:33Z","timestamp":1754233473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095362052500247X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":166,"alternative-id":["S095362052500247X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2025.06.010","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A holistic view of SGLT2 inhibitors: From cardio-renal management to cognitive and andrological aspects","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2025.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}